SLC5A2 and atrial fibrillation: Recent studies have provided conflicting evidence of the effectiveness of sodium-glucose co-transporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in demonstrating a reduction in incident AF in patients with diabetes [26–29].